Targeting LOXL2 for cardiac interstitial fibrosis and heart failure treatment

Nature Communications

Volumn 7, Issue , 2016, Pages

  Yang, Jin ^a,b   Savvatis, Konstantinos ^c   Kang, Jong Seok ^d   Fan, Peidong ^d   Zhong, Hongyan ^d   Schwartz, Karen ^d   Barry, Vivian ^d   Mikels Vigdal, Amanda ^d   Karpinski, Serge ^d   Kornyeyev, Dmytro ^d   Adamkewicz, Joanne ^d   Feng, Xuhui ^a,b   Zhou, Qiong ^a,b   Shang, Ching ^a,e   Kumar, Praveen ^d   Phan, Dillon ^d   Kasner, Mario ^c   López, Begonã ^f   Diez, Javier ^f   Wright, Keith C ^a   Kovacs, Roxanne L ^a   Chen, Peng Sheng ^a   Quertermous, Thomas ^e   Smith, Victoria ^d   Yao, Lina ^d   Tschöpe, Carsten ^c   Chang, Ching Pin ^a,b,d   more..

^a INDIANA UNIVERSITY   (United States)

^b INDIANA UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^d GILEAD SCIENCES   (United States)

^e STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF NAVARRA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

COLLAGEN; LYSYL OXIDASE LIKE 2; OXIDOREDUCTASE; PHOSPHATIDYLINOSITOL 3 KINASE; TRANSFORMING GROWTH FACTOR BETA2; UNCLASSIFIED DRUG; LOXL2 PROTEIN, HUMAN; LOXL2 PROTEIN, MOUSE;

ANTIBODY; BIOTRANSFORMATION; CARDIOVASCULAR DISEASE; CELLS AND CELL COMPONENTS; COLLAGEN; ENZYME ACTIVITY; GENE EXPRESSION; INHIBITION; MOLECULAR ANALYSIS; RODENT; SERUM;

ADULT; AGED; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL MIGRATION; COMPARATIVE STUDY; CONTROLLED STUDY; CRISPR CAS SYSTEM; CRISPR CAS9 SYSTEM; DIASTOLIC DYSFUNCTION; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; FIBROSING ALVEOLITIS; HEART FAILURE; HEART FIBROBLAST; HEART LEFT VENTRICLE ENDDIASTOLIC VOLUME; HEART LEFT VENTRICLE ENDSYSTOLIC VOLUME; HEART LEFT VENTRICLE PRESSURE; HEART MUSCLE FIBROSIS; HEART SIZE; HEART VENTRICLE ENDDIASTOLIC PRESSURE; HEART VENTRICLE FUNCTION; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MALE; MIDDLE AGED; MOLECULAR PATHOLOGY; MOUSE; MYOFIBROBLAST; NONHUMAN; PROTEIN TARGETING; SIGNAL TRANSDUCTION; ANIMAL; BLOOD; CARDIAC MUSCLE; FIBROSIS; KNOCKOUT MOUSE; METABOLISM; PATHOLOGY; PHYSIOLOGICAL STRESS; PHYSIOLOGY;

MUS;

AMINO ACID OXIDOREDUCTASES; ANIMALS; FIBROSIS; HEART FAILURE; HUMANS; MICE, KNOCKOUT; MYOCARDIUM; STRESS, PHYSIOLOGICAL;

EID: 85006056554     PISSN: None     EISSN: 20411723     Source Type: Journal    
DOI: 10.1038/ncomms13710     Document Type: Article

References (44)

1. Go, A. S. et al. Heart disease and stroke statistics-2014 update: a report from the American Heart Association. Circulation 129, e28-e292 (2014).
2. Schelbert, E. B., Fonarow, G. C., Bonow, R. O., Butler, J., Gheorghiade, M. Therapeutic targets in heart failure: refocusing on the myocardial interstitium. J. Am. Coll. Cardiol. 63, 2188-2198 (2014).
3. Butler, J. et al. Developing therapies for heart failure with preserved ejection fraction: current state and future directions. JACC Heart Fail. 2, 97-112 (2014).
4. Davis, J., Molkentin, J. D. Myofibroblasts: trust your heart and let fate decide. J. Mol. Cell. Cardiol. 70, 9-18 (2014).
5. Kong, P., Christia, P., Frangogiannis, N. G. The pathogenesis of cardiac fibrosis. Cell. Mol. Life Sci. 71, 549-574 (2014).
6. Schelbert, E. B. et al. Myocardial fibrosis quantified by extracellular volume is associated with subsequent hospitalization for heart failure, death, or both across the spectrum of ejection fraction and heart failure stage. J. Am. Heart Assoc. 4, e002613 (2015).
7. Hang, C. T. et al. Chromatin regulation by Brg1 underlies heart muscle development and disease. Nature 466, 62-67 (2010).
8. Han, P. et al. A long noncoding RNA protects the heart from pathological hypertrophy. Nature 514, 102-106 (2014).
9. Frantz, S. et al. Tissue inhibitor of metalloproteinases levels in patients with chronic heart failure: an independent predictor of mortality. Eur. J. Heart Fail. 10, 388-395 (2008).
10. Sanada, S. et al. IL-33 and ST2 comprise a critical biomechanically induced and cardioprotective signaling system. J. Clin. Invest. 117, 1538-1549 (2007).
11. Gandhi, P. U., Testani, J. M., Ahmad, T. The current and potential clinical relevance of heart failure biomarkers. Curr. Heart Fail. Rep. 12, 318-327 (2015).
12. Pascual-Figal, D. A., Januzzi, J. L. The biology of ST2: the International ST2 Consensus Panel. Am. J. Cardiol. 115, 3B-7B (2015).
13. Paulus, W. J. et al. How to diagnose diastolic heart failure: a consensus statement on the diagnosis of heart failure with normal left ventricular ejection fraction by the Heart Failure and Echocardiography Associations of the European Society of Cardiology. Eur. Heart J. 28, 2539-2550 (2007).
14. Barry-Hamilton, V. et al. Allosteric inhibition of lysyl oxidase-like-2 impedes the development of a pathologic microenvironment. Nat. Med. 16, 1009-1017 (2010).
15. Creemers, E. E., Pinto, Y. M. Molecular mechanisms that control interstitial fibrosis in the pressure-overloaded heart. Cardiovasc. Res. 89, 265-272 (2011).
16. Rodriguez, H. M. et al. Modulation of lysyl oxidase-like 2 enzymatic activity by an allosteric antibody inhibitor. J. Biol. Chem. 285, 20964-20974 (2010).
17. Hayashi, S., McMahon, A. P. Efficient recombination in diverse tissues by a tamoxifen-inducible form of Cre: a tool for temporally regulated gene activation/inactivation in the mouse. Dev. Biol. 244, 305-318 (2002).
18. Acharya, A., Baek, S. T., Banfi, S., Eskiocak, B., Tallquist, M. D. Efficient inducible Cre-mediated recombination in Tcf21 cell lineages in the heart and kidney. Genesis 49, 870-877 (2011).
19. Sun, Y., Weber, K. T. Infarct scar: a dynamic tissue. Cardiovasc. Res. 46, 250-256 (2000).
20. Willems, I. E., Havenith, M. G., De Mey, J. G., Daemen, M. J. The alpha-smooth muscle actin-positive cells in healing human myocardial scars. Am. J. Pathol. 145, 868-875 (1994).
21. Leask, A. TGFbeta, cardiac fibroblasts, the fibrotic response. Cardiovasc. Res. 74, 207-212 (2007).
22. Hinz, B. Formation and function of the myofibroblast during tissue repair. J. Invest. Dermatol. 127, 526-537 (2007).
23. Hinz, B. et al. The myofibroblast: one function, multiple origins. Am. J. Pathol. 170, 1807-1816 (2007).
24. Hinz, B. et al. Recent developments in myofibroblast biology: paradigms for connective tissue remodeling. Am. J. Pathol. 180, 1340-1355 (2012).
25. Bujak, M., Frangogiannis, N. G. The role of TGF-beta signaling in myocardial infarction and cardiac remodeling. Cardiovasc. Res. 74, 184-195 (2007).
26. Davis, J., Burr, A. R., Davis, G. F., Birnbaumer, L., Molkentin, J. D. A TRPC6-dependent pathway for myofibroblast transdifferentiation and wound healing in vivo. Dev. Cell 23, 705-715 (2012).
27. Hinz, B., Celetta, G., Tomasek, J. J., Gabbiani, G., Chaponnier, C. Alpha-smooth muscle actin expression upregulates fibroblast contractile activity. Mol. Biol. Cell 12, 2730-2741 (2001).
28. Zhang, Y. E. Non-Smad pathways in TGF-beta signaling. Cell Res. 19, 128-139 (2009).
29. Aoyagi, T., Matsui, T. Phosphoinositide-3 kinase signaling in cardiac hypertrophy and heart failure. Curr. Pharm. Des. 17, 1818-1824 (2011).
30. Evans, R. A., Tian, Y. C., Steadman, R., Phillips, A. O. TGF-beta1-mediated fibroblast-myofibroblast terminal differentiation-the role of Smad proteins. Exp. Cell Res. 282, 90-100 (2003).
31. Dobaczewski, M. et al. Smad3 signaling critically regulates fibroblast phenotype and function in healing myocardial infarction. Circ. Res. 107, 418-428 (2010).
32. Verrecchia, F., Chu, M. L., Mauviel, A. Identification of novel TGF-beta/Smad gene targets in dermal fibroblasts using a combined cDNA microarray/promoter transactivation approach. J. Biol. Chem. 276, 17058-17062 (2001).
33. Hu, B. et al. Gut-enriched Kruppel-like factor interaction with Smad3 inhibits myofibroblast differentiation. Am. J. Resp. Cell Mol. Biol. 36, 78-84 (2007).
34. Rohr, S. Myofibroblasts in diseased hearts: new players in cardiac arrhythmias Heart Rhythm 6, 848-856 (2009).
35. Kasner, M. et al. Diastolic tissue Doppler indexes correlate with the degree of collagen expression and cross-linking in heart failure and normal ejection fraction. J. Am. Coll. Cardiol. 57, 977-985 (2011).
36. Lopez, B., Querejeta, R., Gonzalez, A., Larman, M., Diez, J. Collagen cross-linking but not collagen amount associates with elevated filling pressures in hypertensive patients with stage C heart failure: potential role of lysyl oxidase. Hypertension 60, 677-683 (2012).
37. Atsawasuwan, P. et al. Lysyl oxidase binds transforming growth factor-beta and regulates its signaling via amine oxidase activity. J. Biol. Chem. 283, 34229-34240 (2008).
38. Muzumdar, M. D., Tasic, B., Miyamichi, K., Li, L., Luo, L. A global double-fluorescent Cre reporter mouse. Genesis 45, 593-605 (2007).
39. Lopez, B. et al. Impact of treatment on myocardial lysyl oxidase expression and collagen cross-linking in patients with heart failure. Hypertension 53, 236-242 (2009).
40. Trivedi, C. M. et al. Hdac2 regulates the cardiac hypertrophic response by modulating Gsk3 beta activity. Nat. Med. 13, 324-331 (2007).
41. Ran, F. A. et al. Genome engineering using the CRISPR-Cas9 system. Nat. Protoc. 8, 2281-2308 (2013).
42. Yen, S. T. et al. Somatic mosaicism and allele complexity induced by CRISPR/Cas9 RNA injections in mouse zygotes. Dev. Biol. 393, 3-9 (2014).
43. Mashiko, D. et al. Generation of mutant mice by pronuclear injection of circular plasmid expressing Cas9 and single guided RNA. Sci. Rep. 3, 3355 (2013).
44. Stankunas, K. et al. Endocardial Brg1 represses ADAMTS1 to maintain the microenvironment for myocardial morphogenesis. Dev. Cell 14, 298-311 (2008).